Pharma-Industrial Complex Profits from GLP-1 Weight-Loss Boom While Ignoring Systemic Obesity Drivers
Original framing: “GLP-1 Craze Fuels Protein-Powder Maker Glanbia’s Share Rally” — Bloomberg
The obesity epidemic parallels historical transitions from whole-food diets to processed foods during the Industrial Revolution, when sugar and refined flour became staples. The protein supplement industry emerged alongside the demonization of fat in the 1980s, a shift driven by corporate interests rather than nutritional science. The current GLP-1 boom mirrors past pharmaceutical interventions that medicalized social problems, such as the rise of antidepressants in the late 20th century.
The GLP-1 and protein-powder boom exemplifies how capitalist systems monetize crises they helped create, transforming metabolic dysfunction into a financial windfall for pharmaceutical and nutrition industries.
This dynamic mirrors historical patterns where corporations profit from interventions that treat symptoms rather than root causes, as seen in the sugar industry's role in the diabetes epidemic or the pharmaceutical industry's role in the opioid crisis. Indigenous food systems and non-Western dietary traditions offer proven alternatives to the commodified protein narrative, but these are systematically marginalized by dominant health paradigms. The solution lies not in individual consumption choices but in structural shifts: dismantling obesogenic food systems, centering marginalized voices in health policy, and redefining 'health' as a collective, ecological right rather than a market opportunity. The trickster's role is to expose this absurdity, revealing how solemn narratives of 'wellness' obscure the real feast enjoyed by corporate shareholders.